



# Andrew M. Shaughnessy

PARTNER

---

Andy is known for a creative, business-savvy approach, bringing deep scientific fluency and sophisticated litigation strategy to clients in their complex intellectual property disputes.

---

## CONTACT

Toronto: [416.865.8171](tel:416.865.8171)  
[ashaughnessy@torys.com](mailto:ashaughnessy@torys.com)

## Overview

---

Andy's practice focuses on intellectual property litigation and dispute resolution, representing a wide variety of clients in complex patent and trademark infringement and related litigation. With a focus on life sciences, Andy has decades of experience protecting the IP rights of clients in the industry and has deep knowledge and perspective on pharmaceutical patents.

He has appeared before the Supreme Court of Canada, Federal Court of Canada, Federal Court of Appeal, Ontario Superior Court of Justice and Court of Appeal for Ontario, as well as specialized tribunals such as the Trademarks Opposition Board and the Patented Medicine Prices Review Board.

Andy is very active in the legal community and is a well-known speaker, teacher and author in Canada.



He is a fantastic lawyer. He is a very skilled, analytical litigator but he is also pragmatic when it comes to advising on settlements. He is a valued partner.

—CHAMBERS CANADA, 2024

## Featured Work

---

### PATADAY® patent infringement action

Torys acted as counsel to Alcon in defence of a patent infringement action before the Federal Court concerning its ophthalmic drug PATADAY® (olopatadine hydrochloride)

## VIAGRA® tablet trademark dispute

Torys acted as counsel to Pfizer Canada in proceedings before the Trademarks Opposition Board and the Federal Court of Canada concerning the three-dimensional appearance of the VIAGRA® tablet

## LYRICA® PM(NOC) proceedings

Torys acted as counsel to Pfizer Canada in multiple proceedings before the Federal Court of Canada under *PM(NOC) Regulations* concerning patents for LYRICA® (pregabalin), used to treat the symptoms of neuropathic pain and fibromyalgia

Canada's largest telecommunications providers in the joint defence of a patent assertion made by Wi-Lan Inc. over LTE technologies and communications relating to 4G LTE technology

Amgen in multiple proceedings before the Federal Court and the Federal Court of Appeal under the PM(NOC) Regulations concerning its patents for NEUPOGEN® (filgrastim), used in the treatment of neutropenia

Pfizer Canada in proceedings before the Federal Court and Federal Court of Appeal under the PM(NOC) Regulations concerning patents for PRISTIQ® (desvenlafaxine), used in the treatment of depression

a pharmaceutical patentee before the Patented Medicine Prices Review Board in a lengthy hearing on a case involving allegations of excessive pricing

Pfizer Canada in patent infringement proceedings before the Federal Court of Canada concerning patents for quinapril, the active ingredient in its drug ACCUPRIL®

[View More](#)

## Recognition and Awards

---

2016-2027 *Chambers Canada*—Leading lawyer in intellectual property: litigation

---

2008-2026 *Chambers Global*—Leading lawyer in intellectual property: litigation

---

2019-2026 *The Legal 500*—Leading partner in intellectual property, and IP litigation

---

2019-2026 *Managing IP's IP Stars*—Patent star

---

2012-2026 *Benchmark Canada: The Definitive Guide to Canada's Leading Litigation Firms and Attorneys*—Litigation Star (IP)

---

2022 *IAM Global Leaders Guide*—Canada

---

2012-2025 *IAM Patent 1000: The World's Leading Patent Practitioners*—Leading lawyer in litigation

---

2022-2023 *LMG Life Sciences*—Leading life sciences lawyer in intellectual property

---

|           |                                                                                                                                                                     |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2012-2020 | <i>LMG Life Sciences</i> —Life Sciences Star in intellectual property                                                                                               |
| 2006-2026 | <i>Best Lawyers in Canada</i> —Leading lawyer in intellectual property law, and corporate and commercial litigation                                                 |
| 2013-2024 | Lexpert/American Lawyer's <i>Guide to the Leading 500 Lawyers in Canada</i> —Leading lawyer in intellectual property litigation and intellectual property           |
| 2008-2026 | <i>The Canadian Legal Lexpert Directory</i> —Leading lawyer in intellectual property litigation, biotechnology, intellectual property, and life sciences and health |
| 2008-2023 | <i>Who's Who Legal</i> —Global and National leading lawyer in patents, patent litigation and life sciences                                                          |
| 2018      | Lexpert/Thomson Reuters' <i>Guide to the Leading U.S./Canada Cross-Border Corporate Lawyers in Canada</i> —Most frequently recommended in dispute resolution        |
| 2012-2013 | Lexpert's <i>Guide to the Leading US/Canada Cross-border Litigation Lawyers in Canada</i> —Leading lawyer in intellectual property                                  |
| 2013      | <i>Guide to the World's Leading Patent Law Practitioners</i> —Leading Canadian patent lawyer                                                                        |

## Insights

### Federal Court of Appeal limits scope of prohibition against patenting methods of medical treatment

This recent decision from the Federal Court of Appeal confirms that a drug dosing regimen can be a patentable invention in Canada.

#### [2026 IPO Annual Meeting](#)

#### [Patently Absurd, Episode 21: MOMT, FC revisits Gemak v. Jempak, and the “duty to innovate” in Canada](#)

#### [Patently Absurd: IP, the IPO, and Canada, eh?](#)

#### [IPIC 2026 Annual Conference](#)

#### [Consultation on the revised PMPRB proposed Practice Directions](#)

[View More](#)

# News

---

## 83% of Torys' Canadian partners are recognized in *Chambers Canada* 2027

Congratulations to our ranked lawyers and practice groups on earning industry-leading recognition, including 19 Band 1 rankings.

## *Benchmark Litigation* recognizes 22 Torys lawyers in its 2026 guide

[Best Lawyers recognizes 177 Torys lawyers in its 2027 guide](#)

[Chambers Canada ranks 81% of Torys' Canadian partners in its 2026 guide](#)

[176 Torys lawyers recognized in the 2026 Best Lawyers guide](#)

[Torys' strength in patent law recognized by Managing IP](#)

[Seven Torys partners recognized as world leaders in patent law](#)

[View More](#)

## Professional Involvement

---

Andy is a well-known speaker and author in Canada. He is a co-author of *Canadian Patent Act Annotated*. He is an adjunct lecturer at the University of Toronto Faculty of Law, where he oversees the school's participation in the Harold G. Fox Intellectual Property Moot.

Andy is highly active in the legal profession, serving as the Chair of the Court Practices Committee of the Canadian Bar Association and the Secretary of the Canadian Practice Committee of the Intellectual Property Owners Association. He is also a member of the International Patent Enforcement Committee of the Intellectual Property Owners Association; the Litigation Committee, ADR Committee and Intellectual Property Trade Policy Committee of the Intellectual Property Institute of Canada; the Intellectual Property/Information Technology Section of the Ontario Bar Association; the Canadian Society of Chemical Engineers; the American Intellectual Property Law Association (AIPLA); the Intellectual Property Section of the American Bar Association; The Advocates' Society; and the Japan Society.

In the community, Andy is a member of the Applied Science Campaign Cabinet of Queen's University.

## Education and Bar Admissions

---

### Education

LLB, 1991

Queen's University

## Bar Admissions

Ontario, 1993